Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC14247
GDC-0623
RG 7421; MEK inhibitor 1
A potent, ATP-uncompetitive inhibitor of MEK1 -
GC14756
EI1
6-氰基-N-[(1,2-二氢-4,6-二甲基-2-氧代-3-吡啶基)甲基]-1-(1-乙基丙基)-1H-吲哚-4-甲酰胺,KB-145943
A selective inhibitor of EZH2 -
GC17331
Salubrinal
Salubrinal是有效的选择性真核翻译起始因子2α(eIF2α)去磷酸化抑制剂。
-
GC14498
AP20187
B/B Homodimerizer
A CID for FKBP fusion proteins -
GC17430
2-Deoxy-D-glucose
2-脱氧-D-葡萄糖; 2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose
2-Deoxy-D-glucose (2DG),是一种葡萄糖类似物,作为竞争性糖酵解抑制剂。 -
GC14063
GSK1324726A
I-BET726
A selective inhibitor of BET family proteins -
GC11648
BML-277
Chk2 Inhibitor II
A selective DNA damage control kinase inhibitor -
GC13359
Topotecan HCl
盐酸拓扑替康; SKF 104864A Hydrochloride; NSC 609669 Hydrochloride
A potent inhibitor of DNA topoisomerase I -
GC11669
Tamoxifen Citrate
他莫昔芬柠檬酸盐; ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate
A selective estrogen receptor modulator -
GC16233
Tacrolimus (FK506)
他克莫司; FK506; Fujimycin; FR900506
他克莫司 (FK506) 是一种具有强效免疫抑制作用的大环内酯类抗生素,从筑波链霉菌中分离出来,以前曾用于预防人类同种异体移植和治疗自身免疫性疾病。 -
GC17865
Lomustine
洛莫司汀; CCNU; NSC 79037
A DNA alkylating agent -
GC17778
TAME
N-[(4-甲基苯基)磺酰基]-L-精氨酸甲酯
TAME 是后期促进复合物/环体(APC/C 或 APC)的抑制剂,它与 APC/C 结合并阻止其被 Cdc20 和 Cdh1 激活,产生有丝分裂停滞。 TAME 不具有细胞渗透性。 -
GC11177
GDC-0980 (RG7422)
(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮,GDC-0980; GNE 390; RG 7422
A dual inhibitor of PI3K and mTOR -
GC11078
MRS 2578
A selective antagonist of the purinergic P2Y6 receptor
-
GC10354
Daunorubicin HCl
盐酸柔红霉素; Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride
Antitumor antibiotic used in the treatment of acute myeloid leukemias -
GC14007
DCC-2036 (Rebastinib)
N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲酰基)吡啶-4-基)氧]苯基]脲,DCC-2036
An orally bioavailable tyrosine kinase inhibitor -
GC13858
Torin 2
9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮
Selective inhibitor of mTOR -
GC12531
Cabozantinib malate (XL184)
卡博替尼苹果酸盐; XL184 S-malate; BMS-907351 S-malate
A VEGFR2 inhibitor -
GC12415
Rigosertib
瑞格色替; ON-01910
Rigosertib (ON-01910) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3 激酶/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。 -
GC13580
Rigosertib sodium
瑞格色替钠,ON-01910 sodium
Rigosertib sodium (ON-01910 sodium) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3K/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib sodium 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。 -
GC11018
GSK1059615
(5Z)-5-[[4-(4-吡啶基)-6-喹啉基]亚甲基]-2,4-噻唑烷二酮
A potent PI3K inhibitor -
GC11537
MK-4827 tosylate
尼拉帕尼对苯甲磺酸盐; MK-4827 tosylate
An orally bioavailable PARP1/2 inhibitor -
GC12756
MK-4827 hydrochloride
MK-4827 hydrochloride
MK-4827 hydrochloride (MK-4827 hydrochloride) 是一种高效且具有口服生物利用度的 PARP1 和 PARP2 抑制剂,IC50 分别为 3.8 和 2.1 nM。 MK-4827 hydrochloride 抑制 DNA 损伤的修复,激活细胞凋亡并显示出抗肿瘤活性。 -
GC11685
GW5074
A potent inhibitor of Raf-1
-
GC11003
PP121
A potent dual inhibitor of tyrosine and phosphoinositide kinases
-
GC17651
Sunitinib
舒尼替尼; SU 11248
舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC50分别为80nM和2nM。 -
GC15254
Tandutinib (MLN518)
坦度替尼; MLN518; CT53518
An antagonist of PDGFRβ, FLT3, and c-Kit -
GC14675
WYE-125132 (WYE-132)
N-[4-[1-(1,4-二氧杂螺[4.5]癸烷-8-基)-4-(8-氧杂-3-氮杂双环[3.2.1]辛烷-3-基)-1H-吡唑并[3,4-D]嘧啶-6-基]苯基]-N'-甲基脲,WYE-125132
Dual mTORC1/mTORC2 inhibitor -
GC13232
Verbascoside
麦角甾苷; Acteoside; Kusaginin; TJC160
A natural phenylpropanoid glucoside with diverse biological activities -
GC16296
MI-773
(2'R,3S,4'S,5'R)-6-氯-4'-(3-氯-2-氟苯基)-2'-(2,2-二甲基丙基)-1,2-二氢-N-(反式-4-羟基环己基)-2-氧代螺[3H-吲哚-3,3'-吡咯烷]-5'-甲酰胺
MI-773 是一种有效的 MDM2-p53 蛋白-蛋白相互作用 (PPI) 抑制剂,对 MDM2 具有高结合亲和力 (Kd=8.2 nM)。 MI-773 具有抗肿瘤活性。 -
GC11439
MG 149
Tip60 HAT inhibitor
A HAT inhibitor -
GC11488
TCS JNK 5a
JNK Inhibitor IX
A selective inhibitor of JNK2 and JNK3 -
GC12891
CCT007093
(2E,5E)-2,5-二(2-噻吩基亚甲基)环戊酮
An inhibitor of PPM1D -
GC14755
Inauhzin
INZ
A selective SIRT1 inhibitor -
GC14312
Meisoindigo
甲异靛; Dian III; N-Methylisoindigotin; Natura-α
An anticancer agent -
GC10734
Beta-Lapachone
3,4-二氢-2,2-二甲基-2H-萘并[1,2-B]吡喃-5,6-二酮,ARQ-501; NSC-26326
An anti-cancer quinone -
GC16701
SKI II
鞘氨醇激酶抑制剂
An SPHK1 inhibitor -
GC11068
GSK2656157
A PERK inhibitor
-
GC10692
Caffeic Acid Phenethyl Ester
咖啡酸苯乙酯
A potent inhibitor of NF-κB activation -
GC14364
SGI-1027
DNA Methyltransferase Inhibitor II
A DNA methyltransferase inhibitor -
GC15603
JIB-04
5-氯-2(1H)-吡啶酮(2E)-(苯基-2-吡啶基亚甲基)腙
A pan Jumonji histone demethylase inhibitor -
GC15771
PYR-41
An irreversible inhibitor of ubiquitin-activating enzyme
-
GC12011
P276-00
P276-00
P276-00 (P276-00) 是一种有效的细胞周期蛋白依赖性激酶 (CDK) 抑制剂,可抑制 CDK9-cyclinT1、CDK4-cyclin D1 和 CDK1-cyclinB,IC50 分别为 20 nM、63 nM 和 79 nM。 P276-00 (P276-00) 对顺铂耐药细胞具有抗肿瘤活性。 -
GC10294
Tasisulam
他斯索兰,LY 573636
An anticancer agent -
GC16990
Z-LEHD-FMK
Z-LEHD-FMK 是一种选择性且不可逆的 caspase-9 抑制剂,可防止致命的再灌注损伤并减轻细胞凋亡。
-
GC12407
Z-IETD-FMK
CASPASE-8抑制剂,Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone, Z-Ile-Glu(OMe)-Thr-Asp(OMe)-FMK
Z-IETD-FMK(Z-IE(OMe)TD(OMe)-FMK)是一种选择性和细胞可渗透的 caspase-8抑制剂。 -
GC10345
Bay 11-7085
(2E)-3-[[4-叔丁基苯基]磺酰基]-2-丙烯腈,BAY 11-7083
An irreversible inhibitor of IκBα phosphorylation -
GC13592
PD173955
6-(2,6-二氯苯基)-8-甲基-2-[[3-(甲硫基)苯基]氨基]吡啶并[2,3-D]嘧啶-7(8H)-酮
A tyrosine kinase inhibitor -
GC10442
MK-8745
An Aurora A kinase inhibitor
-
GC15828
AMG232
2-((3R,5R,6S)-5-(3-氯苯基)-6-(4-氯苯基)-1-((S)-1-(异丙基磺酰基)-3-甲基丁烷-2-基)-3-甲基-2-氧代哌啶-3-基)乙酸,AMG 232;AMG-232
An inhibitor of the MDM2 and p53 interaction